Effect of pyratrione (a tyrosine hydroxylase inhibitor) in essential hypertension.
1. A clinical study of pyratrione, a tyrosine hydroxylase inhibitor, has been carried out in essential hypertension. 2. Out of thirty-nine patients who received pyratrione, twenty-eight showed a significant decrease in blood pressure.
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011714:Pyrans / Q000627:therapeutic use*; D011753:Pyrones / Q000627:therapeutic use*; D013997:Time Factors; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D011714:Pyrans; D011753:Pyrones; D014446:Tyrosine 3-Monooxygenase